Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis
暂无分享,去创建一个
F. Vera-Badillo | S. Sigurdson | S. Malone | O. Zalay | A. Mahmud | M. Yan
[1] E. Rammant,et al. The incidence and prevalence of upper tract urothelial carcinoma: a systematic review , 2021, BMC Urology.
[2] T. Powles,et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.
[3] G. Facchini,et al. Urologic malignancies: advances in the analysis and interpretation of clinical findings , 2021, Future science OA.
[4] D. Pieper,et al. Managing overlap of primary study results across systematic reviews: practical considerations for authors of overviews of reviews , 2021, BMC Medical Research Methodology.
[5] Huina Wang,et al. Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder. , 2021, The oncologist.
[6] Ming-Hong Chen,et al. Aristolochic acid-associated urinary tract cancers: an updated meta-analysis of risk and oncologic outcomes after surgery and systematic review of molecular alterations observed in human studies , 2021, Therapeutic advances in drug safety.
[7] F. Petros. Epidemiology, clinical presentation, and evaluation of upper-tract urothelial carcinoma , 2020, Translational andrology and urology.
[8] Kun-lin Yang,et al. Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma , 2020, World Journal of Surgical Oncology.
[9] Yee Mun Lee,et al. Optimal Management of Upper Tract Urothelial Carcinoma: Current Perspectives , 2020, OncoTargets and therapy.
[10] Chung‐Han Ho,et al. Concurrent chemoradiotherapy in patients with non‐metastatic upper urinary tract urothelial carcinoma: Report from a single institution in Taiwan , 2020, International journal of urology.
[11] Chun-Chieh Huang,et al. Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway , 2019, Molecules.
[12] Young Seok Kim,et al. Adjuvant Treatments for Advanced Stage, Non-metastatic Upper Tract Urothelial Carcinoma: A Multicenter Study. , 2019, International journal of radiation oncology, biology, physics.
[13] W. Hwang,et al. Randomized trial of adjuvant chemotherapy versus adjuvant radiation therapy for locally advanced bladder cancer after radical cystectomy. , 2019, Journal of Clinical Oncology.
[14] Jianguo Wen,et al. Prognosis and risk factors of patients with upper urinary tract urothelial carcinoma and postoperative recurrence of bladder cancer in central China , 2019, BMC Urology.
[15] T. Sio,et al. Gender Is a Significant Prognostic Factor for Upper Tract Urothelial Carcinoma: A Large Hospital-Based Cancer Registry Study in an Endemic Area , 2019, Front. Oncol..
[16] M. Brundage,et al. Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis. , 2018, Critical reviews in oncology/hematology.
[17] H. Cathro,et al. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas , 2018, The American journal of surgical pathology.
[18] E. B. Butler,et al. The Role of Adjuvant Radiation Therapy in Locally Advanced Bladder Cancer , 2018, Bladder cancer.
[19] W. Hsueh,et al. Adjuvant Radiation Therapy for High Stage Urothelial Carcinoma of the Upper Urinary Tract , 2017 .
[20] Zhuojun Zheng,et al. Prognostic factors and outcomes of primary transitional cell carcinoma of the ureter: a population-based study , 2017, Oncotarget.
[21] X. Yang,et al. Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis , 2016, Oncotarget.
[22] Ying-Hsu Chang,et al. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma , 2016, Scientific Reports.
[23] Steven L. Chang,et al. Upper tract urothelial carcinoma: a different disease entity in terms of management , 2016, ESMO Open.
[24] V. Bhatt,et al. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. , 2016, Anticancer research.
[25] S. Hussain,et al. Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers , 2016, Current Treatment Options in Oncology.
[26] S. Shariat,et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. , 2014, European urology.
[27] Young Seok Kim,et al. Adjuvant radiotherapy for stage III/IV urothelial carcinoma of the upper tract. , 2014, Anticancer research.
[28] M. Babjuk,et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. , 2013, European urology.
[29] David A. Green,et al. Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. , 2012, European urology.
[30] C. Chuang,et al. Adjuvant and salvage radiotherapy for urothelial cell carcinoma of the upper urinary tract: experience in a single institution. , 2012, Chang Gung medical journal.
[31] A. Niemierko,et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. , 2012, European urology.
[32] A. Kibel,et al. Radiotherapy with or Without Chemotherapy in Muscle-Invasive Bladder Cancer , 2012 .
[33] K. Bensalah,et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Raman,et al. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005 , 2011, BJU international.
[35] Yuan Ji,et al. Radiotherapy may improve overall survival of patients with T3/T4 transitional cell carcinoma of the renal pelvis or ureter and delay bladder tumour relapse , 2011, BMC Cancer.
[36] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[37] S. Nakatsuka,et al. [Clinical study of upper urinary tract carcinoma]. , 2009, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.
[38] Y. Lotan,et al. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration , 2009, Cancer.
[39] K. Bensalah,et al. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. , 2009, Urology.
[40] Roger M Harbord,et al. A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints , 2006, Statistics in medicine.
[41] C. Sternberg. Muscle invasive and metastatic bladder cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] T. Sun,et al. Urothelial umbrella cells of human ureter are heterogeneous with respect to their uroplakin composition: different degrees of urothelial maturity in ureter and bladder? , 2005, European journal of cell biology.
[43] A. Zietman,et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. , 2004, The Journal of urology.
[44] R. Sylvester,et al. EAU guidelines on diagnosis and treatment of upper urinary tract transitional cell carcinoma. , 2004, European urology.
[45] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[46] K. Slim,et al. Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument , 2003, ANZ journal of surgery.
[47] A. Zietman,et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. , 2002, Urology.
[48] L. Ellison,et al. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. , 2000, The Journal of urology.
[49] R. Mirimanoff,et al. Prognostic factors in urothelial renal pelvis and ureter tumours: a multicentre Rare Cancer Network study. , 1999, European journal of cancer.
[50] C. Roehrborn,et al. Advanced transitional cell carcinoma of the upper urinary tract: patterns of failure, survival and impact of postoperative adjuvant radiotherapy. , 1998, The Journal of urology.
[51] M. Arrabal Martín,et al. [Efficacy of radiotherapy for upper urinary tract tumor following radical surgery]. , 1998, Archivos españoles de urología.
[52] C. Catton,et al. Transitional cell carcinoma of the renal pelvis and ureter: Outcome and patterns of relapse in patients treated with postoperative radiation. , 1996, Urologic oncology.
[53] M. Housset,et al. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival? , 1996, The Journal of urology.
[54] S. Smalley,et al. Transitional cell carcinoma of the renal pelvis or ureter: patterns of failure. , 1995, Urology.
[55] K. Matsuoka,et al. Analysis of Prognostic Factors in Patients with Pyeloureteral Carcinoma , 1991, American Journal of Clinical Oncology.
[56] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[57] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[58] J. Gart,et al. On the bias of various estimators of the logit and its variance with application to quantal bioassay. , 1967, Biometrika.
[59] Nathan Mantel,et al. Chi-square tests with one degree of freedom , 1963 .
[60] B. Woolf. ON ESTIMATING THE RELATION BETWEEN BLOOD GROUP AND DISEASE , 1955, Annals of human genetics.